This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Biotech Stock Roundup: BMY & REGN Q2 Earnings, Gilead NDA for Coronavirus Drug
by Zacks Equity Research
The biotech sector remains in focus with earnings, regulatory and other pipeline updates.
How Will Biotech ETFs React to Q2 Earnings Release?
by Sweta Jaiswal, FRM
Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their Q2 earnings releases amid the coronavirus crisis.
Alzheimer's in Focus as Biogen's Aducanumab Gets Priority Tag
by Kinjel Shah
If Biogen's (BIIB) aducanumab is approved by the FDA, it will become the first medicine to be approved to reduce the clinical decline associated with Alzheimer's disease.
Mylan (MYL) Q2 Earnings Beat Estimates, Revenues Fall Y/Y
by Zacks Equity Research
Mylan (MYL) beats on both earnings and revenues for the second quarter of 2020.
Ionis (IONS) Q2 Loss Narrower Than Expected, Revenues Miss
by Zacks Equity Research
Ionis (IONS) posts narrower-than-expected Q2 loss. Sales miss estimates.
Biotech Stock Roundup: BIIB Reports Q2, GILD Acquires Stake in Private Company & More
by Zacks Equity Research
The biotech sector remains in focus with earnings, regulatory and other pipeline updates.
Biogen to Pit Spinraza Against Novartis' Zolgensma in Phase IV
by Zacks Equity Research
Biogen (BIIB) intends to start a phase IV study for the assessment of Spinraza's safety in infants and children with SMA who showed a suboptimal clinical response to Novartis' Zolgensma.
AbbVie's Rinvoq Meets Late-Stage Eczema Study Endpoints
by Zacks Equity Research
AbbVie's (ABBV) JAK inhibitor, Rinvoq monotherapy achieves improvement in skin clearance and reduction in itch in significantly higher proportion of atopic dermatitis patients in a phase III study.
Biogen (BIIB) Beats on Q2 Earnings, Raises EPS View, Stock Up
by Zacks Equity Research
Biogen (BIIB) beats second-quarter estimates for both earnings and sales. Stock rises.
Biogen (BIIB) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the extent of the impact of the coronavirus outbreak on Biogen's (BIIB) second-quarter earnings.
Biotech Stock Roundup: GILD, MRNA Give Coronavirus Treatment Updates & More
by Zacks Equity Research
The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.
Biogen/Eisai's New BAN2401 Study for Alzheimer's Begins
by Zacks Equity Research
A new phase III study has been initiated to evaluate Biogen (BIIB) and Eisai's BAN2401 to treat preclinical Alzheimer's disease.
Biogen Files BLA for Alzheimer's Drug Aducanumab, Stock Up
by Zacks Equity Research
If Biogen's (BIIB) aducanumab is approved by the FDA, it will become the first medicine to be approved to reduce the clinical decline associated with Alzheimer's disease.
Mylan Gets Favorable Ruling Against Biogen's Tecfidera Patent
by Zacks Equity Research
Mylan (MYL) wins the district court's decision against Biogen's lead MS drug's patent.
Biogen Falls on Patent Loss of MS Drug Tecfidera to Mylan
by Zacks Equity Research
The U.S. District Court of West Virginia gives a ruling against Biogen (BIIB) over a patent dispute with generic drugmaker Mylan pertaining to its best-selling multiple sclerosis drug, Tecfidera.
Zacks.com featured highlights include: Vistra Energy, Canadian Solar, Biogen and Celestica
by Zacks Equity Research
Zacks.com featured highlights include: Vistra Energy, Canadian Solar, Biogen and Celestica
Biotech Stock Roundup: REGN Begins Coronavirus Study, VRTX, BIIB Give Updates
by Zacks Equity Research
The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.
Unlock the Value of Your Portfolio With 4 Low P/CF Stocks
by Sumit Singh
In value investing, investors pick stocks that are cheap but fundamentally sound. So, the chance of outperformance is high when the market moves higher.
3 Big Biotechs Poised for Growth Amid Coronavirus Pandemic
by Ekta Bagri
We highlight a few leading players from the biotech sector, who are likely to see a good run as the year progresses.
Here's Why You Should Add HMS Holdings to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on HMS Holdings (HMSY) stock, thanks to solid prospects.
PRA Health Boosts Health Harmony COVID-19 Monitoring Program
by Zacks Equity Research
PRA Health (PRAH) gives a boost to COVID-19 Monitoring program through collaboration with the Microsoft Healthcare Bot service.
Regeneron (REGN) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Regeneron (REGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why You Should Retain VEEVA Systems (VEEV) Stock Now
by Zacks Equity Research
Investor confidence is high in VEEVA Systems (VEEV), thanks to solid prospects.
Surmodics Gets CE Mark for SurVeil Drug-Coated Balloon
by Zacks Equity Research
Surmodics' (SRDX) receipt of CE Mark for SurVeil DCB should boost the company's Medical Devices segment.
Hexo Corp. (HEXO) to Post Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Hexo's (HEXO) fiscal third-quarter results are likely to reflect operational efficiency and strong product portfolio.